Group letter re: DEA’s proposed rule on controlled substances quotas

May 4, 2018

RE: Controlled Substances Quotas [Docket No. DEA-480]

The undersigned groups thank the Drug Enforcement Administration (DEA) for the opportunity to comment on its proposed rule regarding controlled substances quotas. Although we support DEA’s efforts to combat diversion, we are concerned that the proposed rule is focused on diversion to the exclusion of another critical factor – drug shortages. To ensure that legitimate medical needs are met, it is imperative that drug shortages be considered as aggregate production quotas (APQ) are set and adjusted.


Read the full letter below.

Related Resources

Letter
Letter to the Senate Finance Committee leadership supporting the Helping to End Addiction and Lessen (HEAL) Substance Use Disorders Act of 2018.
Other Resources
Member
This edition covers an advocacy update, resources for Mental Health Awareness month, and more. 
Advisory
Member
On April 24, the Centers for Medicare…
Advisory
Member
On May 8, the Centers for Medicare…
Letter
Public
AHA's comment on the CMS proposed rule to amend requirements that states assess their Medicaid fee-for-service provider payments to determine if they are…
Letter
Public
AHA comments to HRSA regarding proposed rule that would further delay the effective date for implementing final regulations regarding the 340B Drug Pricing…